BIOLASE Launches Soft-Tissue Diode Laser for Veterinary Applications

Download as PDF

EPIC V-Series Boasts Numerous Special Features: Best Market Pricing; Easy-Installation, Fully-Portable and Lightweight; Patented EZ Tips(R) Technology for Dental and Surgical Procedures; Deep Tissue Handpiece for Pain Therapy; Extended Battery Life; Wireless Technology; Ergonomic Design and Intuitive Touch Screen; On-Line Training

IRVINE, CA -- (Marketwire) -- 02/26/13 -- BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser manufacturer and distributor, announced today that it launched the EPIC V-Series™ veterinary soft-tissue diode laser, at the 85th Western Veterinary Conference held this past February 18-20 in Las Vegas, Nevada. Over 6,500 veterinarians and 15,000 veterinary professionals attended the conference.

The EPIC V-Series soft-tissue diode laser is based on the recently released modular EPIC 10™ platform for medical and dental use. The EPIC V-Series can be used for a wide range of veterinary applications, including surgical, dental, and pain therapy procedures. BIOLASE expects the EPIC V-Series will be available to ship throughout North America and Europe, as well as several other international markets, beginning early in the second quarter of 2013.

The EPIC V-Series has a number of significant features including: pricing that is over 30% less than the competition with comparable technology; easy installation that can be performed by the office staff in just a few minutes; fully-portable, cordless and wireless with a battery that lasts an average work day for surgical and dental procedures; a wireless foot pedal; the lightest unit in the Class 4, 10 watt category, which is ergonomically efficient when moving between exam rooms or for use in a field environment; the only laser on the market with our patented EZ Tips technology for dental and surgical procedures; on-line training through webinars and podcasts; the most aesthetically pleasing laser in veterinary medicine with sleek black ergonomic design and intuitive touch screen; and platform technology that was masterfully designed to allow BIOLASE to easily transition into many different markets by simply adapting the software and providing the appropriate delivery system.

There are approximately 70,000 veterinarians and nearly 34,000 veterinary clinics in North America. This market segment is expected to increase 35 percent over the next 10 years. There are also more than 100,000 veterinarians and 30,000 veterinary clinics in Europe. Further, according to research from the Freedonia Group, a leading international business research company, consumer spending on domesticated animals in the U.S. alone is forecast to reach $44 billion in 2014.

Federico Pignatelli, Chairman and Chief Executive Officer, commented, "We are very pleased to introduce our EPIC soft-tissue diode laser platform into the veterinary market, which is one of many exciting opportunities available for our innovative patented laser technologies. Families seek the very best care for their pets, and the EPIC V-Series allows veterinarians to provide a significantly improved and wider range of treatment solutions. During the recent Western Veterinary Conference, we demonstrated the product and took advance orders. We initially expect to address this fast-growing market segment with our inside sales force and through an online store, and ultimately expand it through a variety of strategic distributor relationships. We are especially excited to apply our technology and vast body of clinical experience in humans for the treatment of gum disease, one of the most serious and common diseases in cats, dogs and horses, and for chronic pain. We look forward to joining other dental companies that have successfully entered and grown their veterinary businesses, including Henry Schein, Inc. (NASDAQ: HSIC), with Butler Schein Animal Health, and Patterson Companies, Inc. (NASDAQ: PDCO), with Webster Veterinary Supply, now called Patterson Veterinary."

The EPIC V-Series features a 940nm wavelength with 10 watts of power as well as an intuitive procedure-based graphical touchscreen. It also uses BIOLASE's proprietary ComfortPulse™ control technology that minimizes tissue damage and avoids pain-inducing heat buildup at the surgical site.

"The EPIC V-Series is more competitively priced than other high-powered lasers in the veterinary market and features a revolutionary and intuitive applications-based user interface. The high-resolution touch screen is pre-programmed with several of the most commonly performed veterinary soft tissue procedures, including pain therapy, which is a highly popular treatment for pets. It is also the only laser in the market with our patented EZ Tips technology for dental and surgical procedures," Pignatelli concluded.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate approximately 290 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 22,000 lasers. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolaseinc, Twitter at twitter.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results, expected outcomes or approvals, or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's product introductions, strategic initiatives, and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current perspective of existing trends and information and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors affecting BIOLASE's business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

Add to Digg Bookmark with del.icio.us Add to Newsvine 

For further information, please contact:
Lisa Wilson
In-Site Communications, Inc.
212-759-3929

Source: BIOLASE, Inc.

Released February 26, 2013